Drug Profile
Research programme: cancer therapeutics - Nerviano Medical Sciences/Genentech
Alternative Names: PNU 652Latest Information Update: 28 Jan 2023
Price :
$50
*
At a glance
- Originator Genentech; Nerviano Medical Sciences
- Class 3-ring heterocyclic compounds; Immunoconjugates; Indoles; Thiophenes
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 12 Dec 2018 Preclinical development is ongoing in USA (Nerviano Medical Sciences pipeline, December 2018)
- 28 Oct 2018 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)